Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

Saint Medical Raises Pre-Series B Funding for Structural Heart Disease Solutions

Fineline Cube Nov 24, 2022

Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly...

Company Drug

Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study

Fineline Cube Nov 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...

Company Drug

Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer

Fineline Cube Nov 24, 2022

China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...

Company Drug

Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug

Fineline Cube Nov 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...

Company Drug

Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne

Fineline Cube Nov 24, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...

Company Drug Legal / IP

FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft

Fineline Cube Nov 23, 2022

US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...

Company Deals

JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston

Fineline Cube Nov 23, 2022

Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...

Company Deals

Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management

Fineline Cube Nov 23, 2022

China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering...

Company Drug

China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study

Fineline Cube Nov 23, 2022

RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...

Policy / Regulatory

Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs

Fineline Cube Nov 23, 2022

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will...

Company Drug

BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting

Fineline Cube Nov 23, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...

Company Deals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

Fineline Cube Nov 23, 2022

Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...

Company Deals Medical Device

Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development

Fineline Cube Nov 23, 2022

Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...

Company Drug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Fineline Cube Nov 23, 2022

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

Fineline Cube Nov 23, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...

Company Drug

InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore

Fineline Cube Nov 23, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...

Company Deals

Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma

Fineline Cube Nov 23, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...

Company Deals

UB Biotechnology Secures Series A Funding for Flow Cytometry Platform

Fineline Cube Nov 22, 2022

China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...

Company Deals

IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform

Fineline Cube Nov 22, 2022

China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...

Policy / Regulatory

Shanghai Unveils Policies to Boost Global Biomedical R&D Hub

Fineline Cube Nov 22, 2022

The Shanghai municipal government has released a set of policies and measures aimed at accelerating...

Posts pagination

1 … 620 621 622 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.